ACC
MCID: ADR016
MIFTS: 48

Adrenal Cortical Carcinoma (ACC)

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

MalaCards integrated aliases for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 40 12
Adrenocortical Carcinoma 40 12 74 52 15
Carcinoma of the Adrenal Cortex 12
Adrenal Cortex Carcinoma 17
Acc 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3948
NCIt 49 C9325
SNOMED-CT 67 255035007
ICD10 32 C74.0
UMLS 71 C0206686

Summaries for Adrenal Cortical Carcinoma

NIH Rare Diseases : 52 Adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex ). These glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. Adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. Girls are more often affected than boys. Symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension , weight gain, frequent urination and possibly deepening of the voice. These symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. Adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. There are a number of genes that have changes (mutations ) that can cause an adrenocortical carcinoma, including TP53 and IGF2 . There have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. An adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol , the hormone released by the adrenal glands. Blood tests can also be conducted to measure levels of potassium and sodium in the blood. A CT scan or MRI may be used to search for a visible tumor in the adrenal cortex. Treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. Chemotherapy , specifically a drug called mitotane , can be used to try to remove any remaining cancer after surgery.

MalaCards based summary : Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to adenoid cystic carcinoma and adrenocortical carcinoma, hereditary. An important gene associated with Adrenal Cortical Carcinoma is HSD11B2 (Hydroxysteroid 11-Beta Dehydrogenase 2), and among its related pathways/superpathways are Proteoglycans in cancer and Corticotropin-releasing hormone signaling pathway. The drugs Bromocriptine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 Adrenocortical carcinoma (ACC) is an aggressive cancer originating in the cortex (steroid... more...

Related Diseases for Adrenal Cortical Carcinoma

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 adenoid cystic carcinoma 33.3 VIM TP53 MUC1 CTNNB1 ACCS
2 adrenocortical carcinoma, hereditary 31.6 TP53 MIR483 IGF2 CTNNB1
3 hypokalemia 31.1 POMC HSD11B2 CYP11B1
4 malignant pheochromocytoma 30.8 SYP MIR483 CHGA
5 conn's syndrome 30.8 POMC HSD11B2 CYP11B2 CYP11B1 CHGA
6 li-fraumeni syndrome 30.7 ZNRF3 TP53 MIR483 IGF2 CTNNB1 ACCS
7 multiple endocrine neoplasia, type i 30.7 SYP POMC MIR483 CHGA
8 angiosarcoma 30.5 VIM TP53 MUC1 MLANA
9 hypoadrenocorticism, familial 30.5 POMC NR5A1 CYP11B2
10 myxoid chondrosarcoma 30.5 SYP MUC1 CHGA
11 adrenal hypoplasia, congenital 30.5 POMC NR5A1 EPPIN
12 acth-independent macronodular adrenal hyperplasia 30.4 POMC MIR483 CYP11B1
13 acinar cell carcinoma 30.4 TP53 SYP IGF2 CTNNB1 CHGA ACCS
14 pleomorphic adenoma 30.4 VIM TP53 MUC1 CTNNB1
15 mucoepidermoid carcinoma 30.4 TP53 MUC1 CTNNB1 CHGA
16 chordoma 30.4 VIM TP53 MUC1 CTNNB1
17 gastrointestinal stromal tumor 30.4 VIM TP53 SYP IGF2 CHGA
18 carcinosarcoma 30.4 VIM TP53 MUC1 CTNNB1
19 lipoid congenital adrenal hyperplasia 30.4 POMC NR5A1 CYP11B2 CYP11B1
20 islet cell tumor 30.4 SYP IGF2 CHGA
21 colorectal adenocarcinoma 30.4 TP53 MUC1 CTNNB1 CHGA
22 small cell carcinoma 30.4 TP53 SYP MUC1 CHGA
23 pseudohermaphroditism 30.4 POMC NR5A1 EPPIN
24 dedifferentiated liposarcoma 30.4 TP53 MUC1 IGF1R
25 neuroendocrine tumor 30.4 SYP POMC IGF1R CHGA
26 mesothelioma, malignant 30.3 VIM MUC1 MIR483 CTNNB1
27 adenoma 30.3 TP53 SYP POMC MUC1 HSD11B2 CYP11B2
28 papilloma of choroid plexus 30.3 TP53 SYP MUC1 IGF2
29 ovary adenocarcinoma 30.3 TP53 MUC1 CTNNB1
30 neurofibroma 30.3 VIM TP53 SYP MUC1 MLANA
31 tubular adenocarcinoma 30.3 SYP MUC1 CTNNB1 CHGA
32 neuroblastoma 30.3 TP53 SYP IGF2 IGF1R CTNNB1 CHGA
33 endocrine gland cancer 30.3 SYP MIR675 MIR483 MIR139 CHGA
34 liposarcoma 30.3 VIM TP53 IGF1R CTNNB1
35 oncocytoma 30.2 VIM SYP MUC1
36 hemangioma 30.2 TP53 SYP MUC1 IGF2 CTNNB1 CHGA
37 adrenal adenoma 30.2 POMC MIR483 IGF2 HSD11B2 EPPIN CYP11B2
38 beckwith-wiedemann syndrome 30.2 ZNRF3 TP53 MIR675 MIR483 IGF2 IGF1R
39 teratoma 30.2 VIM TP53 SYP CTNNB1 CHGA
40 pituitary adenoma, prolactin-secreting 30.1 POMC NR5A1 CHGA
41 adrenal rest tumor 30.1 POMC NR5A1 EPPIN CYP11B2 CYP11B1
42 primary pigmented nodular adrenocortical disease 30.1 SYP POMC MIR483 CTNNB1 CHGA ACCS
43 rhabdomyosarcoma 30.0 VIM TP53 SYP IGF2 IGF1R CTNNB1
44 glioblastoma multiforme 30.0 TP53 SYP MIR139 IGF2 IGF1R CTNNB1
45 ovarian disease 29.9 TP53 POMC MIR483 IGF1R EPPIN CTNNB1
46 adrenal cortical adenoma 29.9 SYP POMC NR5A1 MLANA MIR483 IGF2
47 lung cancer susceptibility 3 29.9 TP53 MUC1 MIR483 MIR139 IGF1R CTNNB1
48 carney complex variant 29.8 ZNRF3 POMC MLANA MIR483 CYP11B1 CTNNB1
49 wilms tumor 1 29.6 TP53 SYP NR5A1 MIR483 IGF2 IGF1R
50 body mass index quantitative trait locus 11 29.5 TP53 POMC NR5A1 MIR675 MIR483 MIR139

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to Adrenal Cortical Carcinoma

Symptoms & Phenotypes for Adrenal Cortical Carcinoma

GenomeRNAi Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CHGA CYP11B1 HSD11B2 IGF1R IGF2 POMC

MGI Mouse Phenotypes related to Adrenal Cortical Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 CHGA CTNNB1 CYP11B1 CYP11B2 HSD11B2 IGF1R
2 endocrine/exocrine gland MP:0005379 9.96 CHGA CTNNB1 CYP11B1 CYP11B2 IGF1R IGF2
3 muscle MP:0005369 9.76 CHGA CTNNB1 CYP11B1 HSD11B2 IGF1R IGF2
4 nervous system MP:0003631 9.7 CHGA CTNNB1 CYP11B2 IGF1R IGF2 NR5A1
5 renal/urinary system MP:0005367 9.23 CHGA CTNNB1 CYP11B1 CYP11B2 HSD11B2 IGF2

Drugs & Therapeutics for Adrenal Cortical Carcinoma

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3 Hormones Phase 4
4 Hormone Antagonists Phase 4
5 Dopamine agonists Phase 4
6 Dopamine Agents Phase 4
7 Neurotransmitter Agents Phase 4
8 Antiparkinson Agents Phase 4
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
11
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Mitotane Approved Phase 3 53-19-0 4211
14
Etoposide Approved Phase 3 33419-42-0 36462
15
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17
Liposomal doxorubicin Phase 3 31703
18 Anti-Bacterial Agents Phase 3
19 Antibiotics, Antitubercular Phase 3
20 Cola Phase 3
21 Liver Extracts Phase 3
22 Anesthetics Phase 3
23 Narcotics Phase 3
24 Analgesics Phase 3
25 Analgesics, Opioid Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Etoposide phosphate Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Tubulin Modulators Phase 3
31 Antimitotic Agents Phase 3
32 Dermatologic Agents Phase 3
33 Keratolytic Agents Phase 3
34 Podophyllotoxin Phase 3 518-28-5
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
37
Indinavir Approved Phase 2 150378-17-9 5362440
38
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
39
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
40
Lactitol Approved, Investigational Phase 2 585-88-6, 585-86-4 493591
41
acetic acid Approved Phase 2 64-19-7 176
42
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
43
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
44
Sodium citrate Approved, Investigational Phase 2 68-04-2
45
Tamoxifen Approved Phase 2 10540-29-1 2733526
46
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
47
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
48
Pembrolizumab Approved Phase 2 1374853-91-4
49
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
50
Ipilimumab Approved Phase 2 477202-00-9

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Unknown status NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
4 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
7 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Recruiting NCT00777244 Phase 3 MITOTANE
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
9 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
10 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
12 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
13 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
14 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
15 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
16 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
17 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
18 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
19 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
20 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
21 An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201) Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
22 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
23 Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
24 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
25 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
26 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
27 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
28 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
29 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
30 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
31 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
32 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
33 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
34 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
35 MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study Recruiting NCT02007148 Phase 2 capecitabine;Docetaxel
36 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
37 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
38 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
39 An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome Enrolling by invitation NCT03604198 Phase 2 relacorilant
40 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04187404 Phase 1, Phase 2
41 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
42 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Not yet recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
43 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
44 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
45 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
47 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
48 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
49 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
50 A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications Completed NCT01772004 Phase 1 Avelumab

Search NIH Clinical Center for Adrenal Cortical Carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

Anatomical Context for Adrenal Cortical Carcinoma

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

40
Cortex, Adrenal Gland, Adrenal Cortex, Testes, Liver, Kidney, Lung

Publications for Adrenal Cortical Carcinoma

Articles related to Adrenal Cortical Carcinoma:

(show top 50) (show all 2928)
# Title Authors PMID Year
1
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. 61
31441020 2020
2
Four cypermethrin isomers induced stereoselective metabolism in H295R cells. 61
32573024 2020
3
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC. 61
32276262 2020
4
A Modern Assessment of Cancer Risk in Adrenal Incidentalomas: Analysis of 2219 Patients. 61
32541223 2020
5
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. 61
32524319 2020
6
Adrenal and Bone Metastases as the Initial Presentation of Endometrial Carcinoma Diagnosed by 18F-FDG PET/CT. 61
32520505 2020
7
Surgical Approach to Abdominal Tumors Involving the Inferior Vena Cava. 61
32558442 2020
8
Report of 2 Pediatric Cases With Li-Fraumeni Syndrome Related Malignancy in a Family. 61
32555031 2020
9
Update on in-vivo preclinical research models in adrenocortical carcinoma. 61
32304391 2020
10
Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. 61
32561853 2020
11
Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey. 61
32438344 2020
12
A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma. 61
32483162 2020
13
Development and validation of prognostic nomograms in patients with adrenocortical carcinoma: a population-based study. 61
32072388 2020
14
Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma. 61
32089260 2020
15
Two subsequent metachroneus solid tumors: Oncocytic variant adrenocortical carcinoma and rhabdomyosarcoma of childhood: Case report and Literature Review. 61
32539319 2020
16
Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma. 61
32522271 2020
17
Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma. 61
32367334 2020
18
Mitotane liposomes for potential treatment of adrenal cortical carcinoma: ex vivo intestinal permeation and in vivo bioavailability. 61
32343624 2020
19
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. 61
32474412 2020
20
[Diffuse retinal pigment epitheliopathy secondary to adrenocortical carcinoma]. 61
32241589 2020
21
Past, Present and Future of Epigenetics in Adrenocortical Carcinoma. 61
32414074 2020
22
Open vs laparoscopic adrenalectomy for localized adrenocortical carcinoma. 61
32421867 2020
23
Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. 61
31900481 2020
24
Adrenocortical tumorigenesis: Lessons from genetics. 61
32507359 2020
25
Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. 61
32451468 2020
26
Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. 61
32448148 2020
27
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. 61
32481732 2020
28
The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. 61
32468513 2020
29
Sustained remission of Lynch syndrome-associated metastatic adrenocortical carcinoma following checkpoint inhibitor therapy-associated multiorgan autoimmunity. 61
32449531 2020
30
Patient and Partner Perspectives on Health-Related Quality of Life in Adrenocortical Carcinoma. 61
32342024 2020
31
Metastatic Adrenocortical Carcinoma Causing Profound Right Ventricular Outflow Tract Obstruction: An Improvement Following Surgical Resection. 61
32370618 2020
32
Copper affects steroidogenesis and viability of human adrenocortical carcinoma (NCI-H295R) cell line in vitro. 61
32437254 2020
33
Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study. 61
32449514 2020
34
Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. 61
31941752 2020
35
Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain. 61
32349159 2020
36
Phytochemical analysis and biological activities of in vitro cultured Nidularium procerum, a bromeliad vulnerable to extinction. 61
32332902 2020
37
Primary adrenal leiomyosarcoma: A case report. 61
32190312 2020
38
Imaging and implications of tumor thrombus in abdominal malignancies: reviewing the basics. 61
31696267 2020
39
HORMONALLY FUNCTIONING ECTOPIC ADRENOCORTICAL CARCINOMA. 61
32339030 2020
40
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. 61
32260362 2020
41
Minimally Invasive Versus Open Adrenalectomy in Patients with Adrenocortical Carcinoma: A Meta-analysis. 61
32277316 2020
42
ASO Author Reflections: Minimally Invasive Versus Open Adrenalectomy in Patients with Adrenocortical Carcinoma: A Meta-analysis. 61
32277318 2020
43
Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. 61
32303972 2020
44
A rare case of oncocytic adrenocortical carcinoma clinically presented as an incidentaloma. 61
32249250 2020
45
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. 61
32283844 2020
46
Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. 61
32295220 2020
47
Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. 61
31241762 2020
48
The outcome of childhood adrenocortical carcinoma in Egypt: A model from developing countries. 61
31971470 2020
49
Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant. 61
32088909 2020
50
A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. 61
32147670 2020

Variations for Adrenal Cortical Carcinoma

Cosmic variations for Adrenal Cortical Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM89368095 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 8

Expression for Adrenal Cortical Carcinoma

Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for Adrenal Cortical Carcinoma

GO Terms for Adrenal Cortical Carcinoma

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.58 POMC CYP11B1 CHGA
2 C21-steroid hormone biosynthetic process GO:0006700 9.46 CYP11B2 CYP11B1
3 cellular response to potassium ion GO:0035865 9.43 CYP11B2 CYP11B1
4 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.37 TP53 MUC1
5 cortisol biosynthetic process GO:0034651 9.32 CYP11B2 CYP11B1
6 cortisol metabolic process GO:0034650 9.26 CYP11B2 CYP11B1
7 aldosterone biosynthetic process GO:0032342 9.16 CYP11B2 CYP11B1
8 regulation of blood volume by renal aldosterone GO:0002017 8.96 HSD11B2 CYP11B2
9 glucocorticoid biosynthetic process GO:0006704 8.8 HSD11B2 CYP11B2 CYP11B1

Molecular functions related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 corticosterone 18-monooxygenase activity GO:0047783 8.96 CYP11B2 CYP11B1
2 steroid 11-beta-monooxygenase activity GO:0004507 8.62 CYP11B2 CYP11B1

Sources for Adrenal Cortical Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....